Nitrosamines: Lessons learnt from sartan medicines
On 23 June 2020, the European medicines regulatory network published the outcome of a lessons learned exercise on the presence of nitrosamines in sartan medicines. This includes recommendations to help reduce the risk of impurities in medicines, and to ensure that regulators are better prepared to manage cases of unexpected impurities. The report is called "Lessons learnt from presence of N-nitrosamine impurities in sartan medicines".
The recommendations include:
- developing additional guidance on:
- the roles and responsibilities of companies involved in the manufacture of medicines;
- controlling impurities;
- good manufacturing practice (GMP);
- sampling and testing.
- improving communication with patients and healthcare professionals;
- expanding cooperation with international partners;
- further developing information technology systems.
These recommendations apply to all medicines.
Source:
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
